174 related articles for article (PubMed ID: 19554396)
1. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
Taniguchi K; Shimazaki C; Fujimoto Y; Shimura K; Uchiyama H; Matsumoto Y; Kuroda J; Horiike S; Taniwaki M
Int J Hematol; 2009 Jul; 90(1):99-102. PubMed ID: 19554396
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
Arita Y; Sakata Y; Sudo T; Maeda T; Matsuoka K; Tamai K; Higuchi K; Shioyama W; Nakaoka Y; Kanakura Y; Yamauchi-Takihara K
Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
4. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
5. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
Akiyama M; Yasuoka H; Takeuchi T
Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
[No Abstract] [Full Text] [Related]
7. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
[TBL] [Abstract][Full Text] [Related]
9. Sequential change in serum VEGF levels in a case of tocilizumab-resistant TAFRO syndrome treated effectively with rituximab.
Wakiya R; Kameda T; Takeuchi Y; Ozaki H; Nakashima S; Shimada H; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jan; 5(1):145-151. PubMed ID: 33269653
[TBL] [Abstract][Full Text] [Related]
10. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
Takeuchi N; Arai T; Kitaichi M; Inoue Y
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24072826
[TBL] [Abstract][Full Text] [Related]
11. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
[TBL] [Abstract][Full Text] [Related]
12. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
13. [Dyspnoea, cough and B symptoms in a 40-year-old woman].
Wolfensberger A; Benz R; Russi EW; Tinguely M; Keller C; Gerber B
Internist (Berl); 2013 Aug; 54(8):1011-5. PubMed ID: 23836253
[TBL] [Abstract][Full Text] [Related]
14. The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K; Murayama S; Ito H; Koga T
Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
[No Abstract] [Full Text] [Related]
16. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schönlein purpura) responding well to tocilizumab: a case report.
Oshima Y; Hoshino J; Suwabe T; Hayami N; Yamanouchi M; Sekine A; Ueno T; Mizuno H; Yabuuchi J; Imafuku A; Kawada M; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Hayashi N; Fujii T; Ubara Y
Clin Rheumatol; 2017 Mar; 36(3):729-733. PubMed ID: 28168662
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement].
Ohno N; Fujiyama S; Ooi M; Haraguchi K; Tokunaga M; Uozumi K; Tsubouchi H
Nihon Naika Gakkai Zasshi; 2007 May; 96(5):988-90. PubMed ID: 17564092
[No Abstract] [Full Text] [Related]
18. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
Seida A; Wada J; Morita Y; Baba M; Eguchi J; Nishimoto N; Okino T; Ichimura K; Yoshino T; Makino H
Am J Kidney Dis; 2004 Jan; 43(1):E3-9. PubMed ID: 14712466
[TBL] [Abstract][Full Text] [Related]
19. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
Mûzes G; Csomor J; Sipos F
Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
[TBL] [Abstract][Full Text] [Related]
20. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]